Single award · contract
COVID-19: Sotrovimab Monoclonal Andtibodies
Award ID: W58P0522C0002
FY2022 · complete year · data as of 2026-07-11
A single federal award, with both ends of the trail linked.
$1.6B
Total award value
Award W58P0522C0002 is a contract from the Department of Defense to Glaxosmithkline, LLC, $1.6B obligated, FY2022 to FY2023, for COVID-19: Sotrovimab Monoclonal Andtibodies. The work is performed in North Carolina. It is classified as NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals). Source
Agency ›
Department of Defense
Source
awarded→$1.6B
Recipient ›
Glaxosmithkline, LLC
Source
performed in→
Description
:COVID-19: Sotrovimab Monoclonal Andtibodies
Award details
Award typeContract
PIIDW58P0522C0002
Action date2021
Period22 mo
Awarding agencyDepartment of Defense →
RecipientGlaxosmithkline, LLC →
Place of performanceNorth Carolina →
CategoryNAICS 325412PSC 6505
Competed?Not recordedSource
Total (exact)$1,597,461,996
More awards to Glaxosmithkline, LLC
awarded 2017$682.2M
awarded 2014$602M
awarded 2012$554.8M
awarded 2020$335.6M
awarded 2021$279.9M
More from Department of Defense
awarded 2016$51.3B
awarded 2017$35.7B
awarded 2017$35.1B
awarded 2001$34.2B
awarded 2011$32B
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.